OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
OKYO Pharma Limited, a clinical-stage biopharmaceutical company focused on neuropathic corneal pain and anterior segment eye diseases, announced its participation in the BTIG Biotechnology Conference 2026. Management will present virtually and offer one-on-one meetings. The company plans to initiate a global Phase 3 pivotal trial in H2 2026 for its…